Published in BMC Med on September 27, 2012
ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol (2014) 4.00
Expression analysis and in silico characterization of intronic long noncoding RNAs in renal cell carcinoma: emerging functional associations. Mol Cancer (2013) 1.18
Carbon nanotubes: an emerging drug carrier for targeting cancer cells. J Drug Deliv (2014) 0.91
Prognostic prediction and diagnostic role of intercellular adhesion molecule-1 (ICAM1) expression in clear cell renal cell carcinoma. J Mol Histol (2014) 0.90
Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma. Front Oncol (2014) 0.85
Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression. Clin Cancer Res (2016) 0.85
Enhanced IMP3 Expression Activates NF-кB Pathway and Promotes Renal Cell Carcinoma Progression. PLoS One (2015) 0.81
Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma. FEBS Open Bio (2014) 0.81
Genome-wide analysis of differentially expressed genes and splicing isoforms in clear cell renal cell carcinoma. PLoS One (2013) 0.80
Soluble Serum αKlotho Is a Potential Predictive Marker of Disease Progression in Clear Cell Renal Cell Carcinoma. Medicine (Baltimore) (2015) 0.79
Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma. Med Sci Monit (2015) 0.79
Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients. Oncotarget (2016) 0.78
The epigenetic landscape of clear-cell renal cell carcinoma. J Kidney Cancer VHL (2015) 0.75
Individualising treatment choices in a crowded treatment algorithm. EJC Suppl (2013) 0.75
A unified pathogenesis for kidney diseases, including genetic diseases and cancers, by the protein-homeostasis-system hypothesis. Kidney Res Clin Pract (2017) 0.75
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
International network of cancer genome projects. Nature (2010) 20.35
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Renal cell carcinoma. Lancet (2009) 6.92
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Exploring the genomes of cancer cells: progress and promise. Science (2011) 6.16
Bring on the biomarkers. Nature (2011) 5.77
BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97
Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res (2008) 4.02
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol (2011) 3.57
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol (2011) 2.75
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med (2005) 2.56
Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol (2011) 2.55
Identification of a microRNA panel for clear-cell kidney cancer. Urology (2009) 2.32
Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol (2011) 2.29
Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A (2001) 2.22
Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol (2011) 2.10
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma. J Urol (2011) 1.91
Misdiagnosis of clear cell renal cell carcinoma. Nat Rev Urol (2011) 1.90
Hypoxia-regulated microRNA-210 modulates mitochondrial function and decreases ISCU and COX10 expression. Oncogene (2010) 1.88
MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One (2011) 1.79
Genome-wide methylation analysis identifies epigenetically inactivated candidate tumour suppressor genes in renal cell carcinoma. Oncogene (2010) 1.69
Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene (2007) 1.63
Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med (2012) 1.62
Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res (2010) 1.57
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol (2011) 1.56
Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene (2010) 1.52
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res (2011) 1.46
The VHL-dependent regulation of microRNAs in renal cancer. BMC Med (2010) 1.46
External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer (2008) 1.45
A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet (2011) 1.34
TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics (2011) 1.20
Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res (2011) 1.12
Predictors of response to targeted therapy in renal cell carcinoma. Arch Pathol Lab Med (2012) 1.10
Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. J Cancer (2011) 1.09
Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics (2012) 1.04
MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun (2011) 1.01
Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma. Am J Pathol (2009) 1.00
Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur Urol (2012) 0.98
Evolution of clinical proteomics and its role in medicine. J Proteome Res (2010) 0.97
GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression. BJU Int (2012) 0.97
Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev Anticancer Ther (2010) 0.93
Epigenetics of kidney cancer and bladder cancer. Epigenomics (2011) 0.91
Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays. PLoS One (2011) 0.83
Differential diagnosis of renal tumours with clear cell histology. Pathology (2010) 0.80
The challenges of harnessing new technology. Eur Urol (2011) 0.77
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol (2004) 5.84
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res (2006) 2.87
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res (2013) 2.45
Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology (2007) 2.45
Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics (2004) 2.43
Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics (2003) 2.17
Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics (2005) 1.69
Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Kidney Int (2013) 1.61
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem (2005) 1.46
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Factor analysis of the Hospital Anxiety and Depression Scale from a large cancer population. Psychol Psychother (2002) 1.40
Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using western blotting. J Pathol (2009) 1.38
A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet (2011) 1.34
Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci (2004) 1.29
Banking of biological fluids for studies of disease-associated protein biomarkers. Mol Cell Proteomics (2008) 1.27
Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res (2005) 1.27
Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res (2003) 1.26
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res (2007) 1.25
A Rasch and factor analysis of the Functional Assessment of Cancer Therapy-General (FACT-G). Health Qual Life Outcomes (2007) 1.19
Mining the archival formalin-fixed paraffin-embedded tissue proteome: opportunities and challenges. Mol Biosyst (2008) 1.18
The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. Psychooncology (2008) 1.18
CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol (2008) 1.17
Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. Exp Cell Res (2005) 1.13
Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer (2006) 1.12
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res (2011) 1.12
Psychosocial care for cancer patients in primary care? Recognition of opportunities for cancer care. Fam Pract (2004) 1.11
Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics (2006) 1.10
Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol (2002) 1.10
Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial. Eur J Cancer (2010) 1.09
Impact of patient-reported outcomes in oncology: a longitudinal analysis of patient-physician communication. J Clin Oncol (2011) 1.09
Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: assessment of overall technical variability and the impact of block age. Proteomics Clin Appl (2013) 1.08
Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations. J Proteome Res (2010) 1.07
Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clin Appl (2010) 1.04
Integrated multi-level quality control for proteomic profiling studies using mass spectrometry. BMC Bioinformatics (2008) 1.04
A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics (2011) 1.02
Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene (2005) 1.01
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun (2005) 0.99
Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer (2005) 0.96
Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clin Cancer Res (2008) 0.96
Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One (2012) 0.95
Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function. Proteomics (2009) 0.94
The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res (2003) 0.92
Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics (2006) 0.92
Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer (2014) 0.92
Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. Proteomics (2009) 0.91
Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int (2013) 0.90
Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol (2002) 0.90
Impact of pre-analytical factors on the proteomic analysis of formalin-fixed paraffin-embedded tissue. Proteomics Clin Appl (2013) 0.89
Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. Proteomics (2009) 0.89
Serum biomarker discovery in renal cancer using 2-DE and prefractionation by immunodepletion and isoelectric focusing; increasing coverage or more of the same? Proteomics (2008) 0.87
Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Rev (2013) 0.87
Measuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions. Ann Clin Biochem (2011) 0.87
Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers. Nat Rev Urol (2013) 0.87
Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma. Br J Haematol (2007) 0.87
Key clinical issues in renal cancer: a challenge for proteomics. World J Urol (2007) 0.87
Development of an advanced database for clinical trials integrated with an electronic patient record system. Comput Biol Med (2011) 0.86
Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics (2003) 0.86
Proteomic profiling using mass spectrometry--does normalising by total ion current potentially mask some biological differences? Proteomics (2008) 0.85
Impact of preanalytical variables on the analysis of biological fluids in proteomic studies. Proteomics Clin Appl (2007) 0.85
The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst (2002) 0.85
The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer. Clin Cancer Res (2004) 0.84
Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker. Eur J Cancer (2012) 0.84
Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol (2008) 0.84